Experimental Hematology
Volume 38, Issue 1 , Pages 20-26 , January 2010

Constant BCR-ABL transcript level ≥0.1% (IS) in patients with CML responding to imatinib with complete cytogenetic remission may indicate mutation analysis

  • Kateřina Machová Poláková

      Affiliations

    • Institute of Hematology and Blood Transfusion, Department of Molecular Genetics, Prague, Czech Republic
    • Corresponding Author InformationOffprint requests to: Kateřina Machová Poláková, Ph.D., Institute of Hematology and Blood Transfusion, Department of Molecular Genetics, U Nemocnice 1, 128 20 Praha, Czech Republic
    • ,
  • Václava Polívková

      Affiliations

    • Institute of Hematology and Blood Transfusion, Department of Molecular Genetics, Prague, Czech Republic
    • ,
  • Jana Rulcová

      Affiliations

    • Institute of Hematology and Blood Transfusion, Department of Molecular Genetics, Prague, Czech Republic
    • ,
  • Hana Klamová

      Affiliations

    • Institute of Hematology and Blood Transfusion, Clinical Department, Prague, Czech Republic
    • ,
  • Tomáš Jurček

      Affiliations

    • Department of Internal Medicine, Hematology and Oncology, Center of Molecular Biology and Gene Therapy, Faculty Hospital Brno and Masaryk University, Brno, Czech Republic
    • ,
  • Dana Dvořáková

      Affiliations

    • Department of Internal Medicine, Hematology and Oncology, Center of Molecular Biology and Gene Therapy, Faculty Hospital Brno and Masaryk University, Brno, Czech Republic
    • ,
  • Daniela Žáčková

      Affiliations

    • Department of Internal Medicine, Hematology and Oncology, Faculty Hospital Brno and Masaryk University, Brno, Czech Republic
    • ,
  • Zdeněk Pospíšil

      Affiliations

    • Department of Mathematics and Statistics, Faculty of Science, Masaryk University, Brno, Czech Republic
    • ,
  • Jiří Mayer

      Affiliations

    • Department of Internal Medicine, Hematology and Oncology, Faculty Hospital Brno and Masaryk University, Brno, Czech Republic
    • ,
  • Jana Moravcová

      Affiliations

    • Institute of Hematology and Blood Transfusion, Department of Molecular Genetics, Prague, Czech Republic

Received 13 August 2009 ,Revised 8 October 2009 ,Accepted 12 October 2009.

References 

  1. Cang S, Liu D. P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia. J Hematol Oncol. 2008;1:15
  2. Lahaye T, Riehm B, Berger U, et al. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center—A 4.5-year follow-up. Cancer. 2005;103:1659–1669
  3. Khorashad JS, de Lavallade H, Apperley JF, et al. Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression. J Clin Oncol. 2008;26:4806–4813
  4. Gabert J, Beillard E, van der Velden VHJ, et al. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia—A Europe Against Cancer Program. Leukemia. 2003;17:2318–2357
  5. Rulcova J, Zmekova V, Zemanova Z, Klamova H, Moravcova J. The effect of total-ABL, GUS and B2M control genes on BCR-ABL monitoring by real-time RT-PCR. Leuk Res. 2007;31:483–491
  6. Poláková KM, Lopotova T, Klamova H, Moravcova J. High-resolution melt curve analysis: Initial screening for mutations in BCR-ABL kinase domain. Leuk Res. 2008;32:1236–1243
  7. Branford S, Hughes T. Detection of BCR-ABL mutation and resistance to imatinib mesylate. In:  Iland H,  Hertzberg M,  Marlton P editor. Myeloid leukemia: methods and protocols. Totowa, NJ: Humana Press Inc.; 2005;p. 93–106
  8. Willis SG, Lange T, Demehri S, et al. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients; correlation with clonal cytogenetic evolution but not response to therapy. Blood. 2005;106:2128–2137
  9. Moravcova J, Zmekova V, Klamova H, et al. Differences and similarities in kinetics of BCR-ABL transcript levels in CML patients treated with imatinib mesylate for chronic or accelerated disease phase. Leuk Res. 2004;28:415–419
  10. Polakova KM, Zmekova V, Rulcova J, Klamova H, Zemanova Z, Moravcova J. BCR-ABL mutations in chronic myeloid leukemia - Not only detection. Leuk Lymph. 2008;49:1620–1622
  11. Redaelli S, Piazza R, Rostagno R, et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol. 2009;27:469–471
  12. Branford S, Rudzki Z, Walsh S, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood. 2003;102:276–283
  13. Soverini S, Martinelli G, Rosti G, et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA working party on chronic myeloid leukemia. J Clin Oncol. 2005;23:4100–4109
  14. Marin D, Milojkovic D, Olavarria E, et al. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood. 2008;112:4437–4444
  15. Quintás-Cardama A, Kantarjian H, Jones D, et al. Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patiens with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood. 2009;18:6315–6321
  16. Branford S, Rudzki Z, Parkinson I, et al. Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood. 2004;104:2926–2932
  17. Press RD, Love Z, Tronnes AA, et al. BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML. Blood. 2006;107:4250–4256
  18. Kantarjian H, Schiffer C, Jones D, Cortes J. Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods. Blood. 2008;111:1774–1780
  19. Press RD, Willis SG, Laudadio J, Mauro MJ, Deininger MWN. Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib. Blood. 2009;114:2598–2605

PII: S0301-472X(09)00394-4

doi: 10.1016/j.exphem.2009.10.003

Experimental Hematology
Volume 38, Issue 1 , Pages 20-26 , January 2010

Article Tools

* Image Usage & Resolution